Results 161 to 170 of about 165,865 (302)

Mecanismos moleculares en la carcinogénesis: Alteraciones celulares y su impacto en la progresión tumoral

Correo Científico Médico
La carcinogénesis es un proceso complejo que implica alteraciones moleculares en células normales, facilitando su transformación en neoplasias malignas.
David Ismael Pérez Aldás, Micaela Carolina Chato Heredia, Gabriela Belén Gutiérrez Rocha   +2 more
doaj  

Extrachromosomal DNA Amplification as a Prognostic Factor for Cancer. [PDF]

J Pers Med
Gajewski F, Pec J, Kleinrok J, Pająk W, Pacyna K, Tokarzewska A, Krawczyk P.   +6 more
europepmc   +1 more source

Oncogenic osteomalacia [PDF]

QJM: An International Journal of Medicine, 2018
Annamalai, AK, Gill, AJ, Shinto, A, Sivakumar, R, Singhi, PK, Prabhu, VA, Gopalakrishnan, C, Chelian, M, Sridhar, S, Shanthi, R, Puri, V, Gururaj, N, Srinivasan, KG, Clifton-Bligh, R, Gurnell, M   +14 more
openaire   +2 more sources

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma. [PDF]

Clin Transl Sci
Xu L, Sadanand A, Neczypor EW, Liu YT, Butler E, Moore K, Bowman F, Mazumder Y, Naranjo A, Chlenski A, Xiao X, Guo L, Cohn SL, Applebaum MA, Skapek SX.   +14 more
europepmc   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer. [PDF]

iScience
Ishida M, Yamada T, Goto Y, Otsuki T, Taniguchi H, Harada T, Yoshimura A, Shiotsu S, Okada A, Jinno K, Kanda H, Inoguchi N, Fukui M, Yamada T, Hata T, Kawachi H, Katayama Y, Morimoto K, Iwasaku M, Kijima T, Takayama K.   +20 more
europepmc   +1 more source

Silencing the Agrobacterium tumefaciens oncogenes

Crown gall disease is an agricultural problem caused by the soil-borne bacterium, Agrobacterium tumefaciens. A. tumefaciens oncogenes cause transformed plant cells to overproduce the hormones, auxin and cytokinin.
Pitrak, Jennifer
core  

A Non‐Canonical Role of SMAD4 in Regulating 3D Genome Architecture to Inhibit Lung Squamous Cell Carcinoma Development

Advanced Science, EarlyView.
SMAD4 is identified as a guardian of 3D genome architecture in lung squamous cell carcinoma. Loss of SMAD4 unleashes EP300 at chromatin loop anchors, strengthening enhancer–promoter looping and H3K27ac at the SOX2 locus to drive aberrant SOX2 activation and tumor cell proliferation.
Qian Tang, Chen Lian, Xinyan Han, Xuhan Zhang, Zihan Wang, Boyu Wang, Taoyu Zhu, Xinrui Lin, Xiaolei Wang, Yaping Xu, Manyu Xiao, Zijin Wang, Junming Li, Silin Chen, Yunze Wang, Yufei Liu, Songsong Li, Zuolin Shen, Xi Lu, Xueqi Han, Yilu Zhou, Mingyang Xiao, Jiayi Ran, Xiaoran Cao, Xinyi Xu, Hugo Sámano‐Sánchez, Alfredo Rodríguez, Lian Wang, Shuifang Chen, Zhanyu Xu, Shirong Zhang, Nuo Yang, Yong Tang, Jian Liu   +33 more
wiley   +1 more source

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer. [PDF]

Target Oncol
Wakatsuki T, Yamamoto N, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Hirano H, Shoji H, Yamaguchi T, Chin K, Ogura M, Nakayama I, Osumi H, Ueki A, Kitano S, Boku N, Yamaguchi K, Takahari D.   +17 more
europepmc   +1 more source